



Clinical trial results:

A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 1 year in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF agents (CAIN457F2309) and A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis (CAIN457F2309E1)

Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use <https://www.novctrd.com/CtrdWeb/home.novfor> complete trial results.

Summary

EudraCT number	2012-002760-27
Trial protocol	CZ HU DE SK IT BG ES
Global end of trial date	14 May 2015

Results information

Result version number	v1 (current)
This version publication date	11 July 2018
First version publication date	11 July 2018

Trial information

Trial identification

Sponsor protocol code	CAIN457F2309 and CAIN457F2309E1
-----------------------	---------------------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01350804
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
--	----

Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 May 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	14 May 2015
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Core: To demonstrate that the efficacy of secukinumab 75 mg or 150 mg at Week 24 is superior to placebo in patients with active RA based on the proportion of patients achieving an ACR20 response.

Extension: To evaluate the long-term efficacy of secukinumab 75 and 150 mg (provided as prefilled syringes) with respect to ACR20, ACR50 and ACR70 response over time up to Month 60 in patients with active rheumatoid arthritis who had previously experienced an inadequate or intolerant response to anti-TNF- α therapy and who completed the core study CAIN457F2309.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 September 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Brazil: 37
Country: Number of subjects enrolled	Bulgaria: 35
Country: Number of subjects enrolled	Canada: 3
Country: Number of subjects enrolled	Colombia: 35
Country: Number of subjects enrolled	Czech Republic: 30
Country: Number of subjects enrolled	France: 15
Country: Number of subjects enrolled	Germany: 122
Country: Number of subjects enrolled	Hungary: 14
Country: Number of subjects enrolled	Italy: 17
Country: Number of subjects enrolled	Mexico: 62

Country: Number of subjects enrolled	Romania: 1
Country: Number of subjects enrolled	Russian Federation: 22
Country: Number of subjects enrolled	Slovakia: 2
Country: Number of subjects enrolled	Spain: 27
Country: Number of subjects enrolled	United States: 129
Worldwide total number of subjects	551
EEA total number of subjects	263

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	435
From 65 to 84 years	115
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

At week 16, placebo responders and non-responders were re-randomized to AIN457 75mg or AIN457 150mg. Abatacept responders at Week 16 continued on abatacept. Abatacept non-responders at Week 16 were re-randomized to AIN457 75mg or AIN457 150mg.

Pre-assignment

Screening details:

One patient was randomized to AIN457 75mg but instead received placebo up to week 16 and was re-categorized to placebo in the Safety Set for the first 16 weeks. Past week 16, this patient received secukinumab and was included in the "Any AIN457 75mg" for long term safety analyses.

Period 1

Period 1 title	Core Study
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject, Monitor, Carer, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	AIN457 10mg/kg - 75 mg

Arm description:

Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.

Arm type	Experimental
Investigational medicinal product name	AIN457
Investigational medicinal product code	
Other name	Secukinumab
Pharmaceutical forms	Powder for solution for injection/infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.

Arm title	AIN457 10mg/kg - 150 mg
------------------	-------------------------

Arm description:

Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.

Arm type	Experimental
Investigational medicinal product name	AIN457
Investigational medicinal product code	
Other name	Secukinumab
Pharmaceutical forms	Powder for solution for injection/infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.

Arm title	Placebo
------------------	---------

Arm description:

Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status ($\geq 20\%$ reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection/infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status treatment at week 16. Responders were switched to active treatment at week 24.

Arm title	Abatacept
------------------	-----------

Arm description:

Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).

Arm type	Active comparator
Investigational medicinal product name	Abatacept
Investigational medicinal product code	
Other name	Orencia
Pharmaceutical forms	Powder for concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received abatacept (from 500 to 1000 mg i.v. based on weight) up until week 16. At week 16, participants who responded to abatacept maintained treatment with abatacept for the duration of the study. Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).

Number of subjects in period 1	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo
Started	138	137	138
Safety set	137	136	138
Treatment switch to AIN457 at week 16	0 ^[1]	0 ^[2]	78 ^[3]
Treatment switch to AIN457 at week 24	0 ^[4]	0 ^[5]	45 ^[6]
Full Analysis Set	138	137	138
Completed	97	90	91
Not completed	41	47	47
Adverse event, serious fatal	1	1	1
Consent withdrawn by subject	11	17	16
Physician decision	1	-	1
Study terminated by Sponsor	-	-	-
Adverse event, non-fatal	8	10	8
Protocol deviation	1	-	1
Lost to follow-up	3	-	2
Lack of efficacy	16	19	18

Number of subjects in period 1	Abatacept
Started	138

Safety set	137
Treatment switch to AIN457 at week 16	0 [7]
Treatment switch to AIN457 at week 24	37 [8]
Full Analysis Set	138
Completed	112
Not completed	26
Adverse event, serious fatal	-
Consent withdrawn by subject	7
Physician decision	3
Study terminated by Sponsor	2
Adverse event, non-fatal	8
Protocol deviation	-
Lost to follow-up	1
Lack of efficacy	5

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Crossover of placebo non responders arm to active treatment arms in a 1:1 randomized manner

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Crossover of placebo non responders arm to active treatment arms in a 1:1 randomized manner

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Crossover of placebo non responders arm to active treatment arms in a 1:1 randomized manner

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Crossover of placebo non responders arm to active treatment arms in a 1:1 randomized manner

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Crossover of placebo non responders arm to active treatment arms in a 1:1 randomized manner

[6] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Crossover of placebo non responders arm to active treatment arms in a 1:1 randomized manner

[7] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Crossover of placebo non responders arm to active treatment arms in a 1:1 randomized manner

[8] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Crossover of placebo non responders arm to active treatment arms in a 1:1 randomized manner

Period 2

Period 2 title	Extension Study, weeks 52 - 260
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	AIN457 10mg/kg - 75 mg

Arm description:

Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.

Arm type	Experimental
Investigational medicinal product name	AIN457
Investigational medicinal product code	
Other name	Secukinumab
Pharmaceutical forms	Powder for solution for injection/infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.

Arm title	AIN457 10mg/kg - 150 mg
------------------	-------------------------

Arm description:

Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.

Arm type	Experimental
Investigational medicinal product name	AIN457
Investigational medicinal product code	
Other name	Secukinumab
Pharmaceutical forms	Powder for solution for injection/infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.

Arm title	Placebo
------------------	---------

Arm description:

Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status ($\geq 20\%$ reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection/infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status ($\geq 20\%$ reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.

Arm title	Abatacept
------------------	-----------

Arm description:

Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not

respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).

Arm type	Active comparator
Investigational medicinal product name	Abatacept
Investigational medicinal product code	
Other name	Orencia
Pharmaceutical forms	Powder for concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received abatacept (from 500 to 1000 mg i.v. based on weight) up until week 16. At week 16, participants who responded to abatacept maintained treatment with abatacept for the duration of the study. Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).

Number of subjects in period 2^[9]	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo
Started	80	79	72
Completed	0	0	0
Not completed	80	79	72
Consent withdrawn by subject	5	6	4
Physician decision	1	-	2
Study terminated by Sponsor	67	67	64
Adverse event, non-fatal	3	1	2
Lost to follow-up	-	1	-
Lack of efficacy	4	4	-

Number of subjects in period 2^[9]	Abatacept
Started	23
Completed	0
Not completed	23
Consent withdrawn by subject	3
Physician decision	-
Study terminated by Sponsor	16
Adverse event, non-fatal	3
Lost to follow-up	-
Lack of efficacy	1

Notes:

[9] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Not all patients completing the previous milestone continued on in the extension study

Baseline characteristics

Reporting groups

Reporting group title	AIN457 10mg/kg - 75 mg
Reporting group description:	Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.
Reporting group title	AIN457 10mg/kg - 150 mg
Reporting group description:	Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.
Reporting group title	Placebo
Reporting group description:	Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status ($\geq 20\%$ reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.
Reporting group title	Abatacept
Reporting group description:	Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).

Reporting group values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo
Number of subjects	138	137	138
Age Categorical Units: Participants			
<=18 years	0	0	0
Between 18 and 65 years	111	103	106
>=65 years	27	34	32
Age continuous Units:	54.9 ± 11.32	55.9 ± 12.27	55.5 ± 12.05
Gender, Male/Female Units: Participants			
Female	119	109	115
Male	19	28	23

Reporting group values	Abatacept	Total	
Number of subjects	138	551	
Age Categorical Units: Participants			
<=18 years	0	0	
Between 18 and 65 years	115	435	
>=65 years	23	116	
Age continuous Units:	51.6 ± 12.39	-	

Gender, Male/Female			
Units: Participants			
Female	107	450	
Male	31	101	

End points

End points reporting groups

Reporting group title	AIN457 10mg/kg - 75 mg
Reporting group description: Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.	
Reporting group title	AIN457 10mg/kg - 150 mg
Reporting group description: Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.	
Reporting group title	Placebo
Reporting group description: Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status ($\geq 20\%$ reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.	
Reporting group title	Abatacept
Reporting group description: Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).	
Reporting group title	AIN457 10mg/kg - 75 mg
Reporting group description: Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.	
Reporting group title	AIN457 10mg/kg - 150 mg
Reporting group description: Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.	
Reporting group title	Placebo
Reporting group description: Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status ($\geq 20\%$ reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.	
Reporting group title	Abatacept
Reporting group description: Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).	
Subject analysis set title	Placebo non-responder - AIN457 75mg
Subject analysis set type	Full analysis
Subject analysis set description: Participants switched from placebo to AIN457 75 mg starting at week 16.	
Subject analysis set title	Placebo non-responder - AIN457 150mg
Subject analysis set type	Full analysis
Subject analysis set description: Participants switched from placebo to AIN457 150 mg starting at week 16.	
Subject analysis set title	Placebo responder - AIN457 75mg
Subject analysis set type	Full analysis
Subject analysis set description: Participants switched from placebo to AIN457 75 mg starting at week 24.	
Subject analysis set title	Placebo responder - AIN457 150mg
Subject analysis set type	Full analysis

Subject analysis set description:

Participants switched from placebo to AIN457 150 mg starting at week 24.

Subject analysis set title	Abatacept responders
Subject analysis set type	Full analysis

Subject analysis set description:

Abatacept responders remained on abatacept (from 500 to 1000 mg iv based on weight).

Subject analysis set title	Abatacept non-responders - AIN457 75mg
Subject analysis set type	Full analysis

Subject analysis set description:

Participants switched from abatacept to AIN457 75 mg starting at week 24.

Subject analysis set title	Abatacept non-responders - AIN457 150mg
Subject analysis set type	Full analysis

Subject analysis set description:

Participants switched from abatacept to AIN457 150 mg starting at week 24.

Primary: Percentage of participants achieving an American College of Rheumatology Response 20 (ACR20).

End point title	Percentage of participants achieving an American College of Rheumatology Response 20 (ACR20).
-----------------	---

End point description:

ACR20 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20% improvement in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR)). The ACR20 response results at week 24 used non-responder imputation.

End point type	Primary
----------------	---------

End point timeframe:

week 24

End point values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	138	138
Units: Percentage of participants				
number (not applicable)	28.3	30.7	18.1	42.8

Statistical analyses

Statistical analysis title	ACR20 in AIN457 10mg/kg - 75 mg versus placebo
Comparison groups	AIN457 10mg/kg - 75 mg v Placebo

Number of subjects included in analysis	276
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0458
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	1
upper limit	3.2

Statistical analysis title	ACR20 in AIN457 10mg/kg - 150 mg versus placebo
Comparison groups	AIN457 10mg/kg - 150 mg v Placebo
Number of subjects included in analysis	275
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0152
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	2.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.1
upper limit	3.5

Secondary: Change from baseline in Disease Activity Score utilizing CRP (DAS28-CRP)

End point title	Change from baseline in Disease Activity Score utilizing CRP (DAS28-CRP)
End point description:	
<p>The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement.</p>	
End point type	Secondary
End point timeframe:	
baseline, week 24	

End point values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	116	108	44	84
Units: score on a scale				
least squares mean (standard error)	-1.47 (± 0.115)	-1.47 (± 0.119)	-1.02 (± 0.163)	-2.07 (± 0.128)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)

End point title	Change from baseline in Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)
-----------------	--

End point description:

The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, "are you able to..." perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.

End point type	Secondary
----------------	-----------

End point timeframe:
baseline, week 24

End point values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	117	110	44	86
Units: score on a scale				
least squares mean (standard error)	-0.3 (± 0.049)	-0.39 (± 0.051)	-0.26 (± 0.065)	-0.61 (± 0.053)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants achieving ACR50

End point title	Percentage of participants achieving ACR50
-----------------	--

End point description:

ACR50 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 50% improvement in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA

pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR50 response results at week 24 used non-responder imputation.

End point type	Secondary
End point timeframe:	week 24

End point values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	138	138
Units: Percentage of participants				
number (not applicable)	11.6	16.8	9.4	27.5

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants achieving ACR20, ACR 50 and ACR 70 - using non-responder imputation

End point title	Percentage of participants achieving ACR20, ACR 50 and ACR 70 - using non-responder imputation
-----------------	--

End point description:

ACR20, ACR 50 and ACR 70 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20%, 50% and/or 70% improvement, respectively, in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR).

End point type	Secondary
----------------	-----------

End point timeframe:

baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24

End point values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	138	138
Units: Percentage of participants				
number (not applicable)				
ACR20, week 1	21	17.5	7.2	10.9
ACR20, week 2	24.6	21.2	12.3	23.9
ACR20, week 4	34.1	27	21.7	31.2
ACR20, week 8	35.5	41.6	21	49.3
ACR20, week 12	28.3	33.6	24.6	47.1

ACR20, week 16	34.1	39.4	23.2	51.4
ACR20, week 20	26.8	38	18.1	47.8
ACR20, week 24	28.3	30.7	18.1	42.8
ACR50, week 1	6.5	2.9	0.7	1.4
ACR50, week 2	5.1	8.8	2.9	2.9
ACR50, week 4	9.4	10.2	2.9	7.2
ACR50, week 8	7.2	15.3	10.1	18.8
ACR50, week 12	8.7	13.1	10.1	22.5
ACR50, week 16	13.8	20.4	9.4	23.9
ACR50, week 20	12.3	18.2	8	26.8
ACR50, week 24	11.6	16.8	9.4	27.5
ACR70, week 1	0.7	0.7	0	0.7
ACR70, week 2	1.4	0.7	1.4	0.7
ACR70, week 4	4.3	2.9	1.4	1.4
ACR70, week 8	1.4	4.4	2.9	5.8
ACR70, week 12	2.2	2.9	2.9	9.4
ACR70, week 16	5.1	8	2.9	9.4
ACR70, week 20	4.3	7.3	5.8	10.1
ACR70, week 24	5.1	10.2	5.1	12.3

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants achieving ACR20, ACR 50 and ACR 70 - observed data

End point title	Percentage of participants achieving ACR20, ACR 50 and ACR 70 - observed data
-----------------	---

End point description:

ACR20, ACR 50 and ACR 70 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20%, 50% and/or 70% improvement, respectively, in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR)). The ACR20, ACR50 and ACR70 response results from baseline up to week 52 were based on observed data, i.e. without imputation.

End point type	Secondary
----------------	-----------

End point timeframe:

baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	138	138
Units: Percentage of participants number (not applicable)				
ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,1	22.7	18.6	7.7	11.5

ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,1	26.7	22.3	12.7	25.4
ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,1	36.1	28	22.9	34.1
ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,1	38.6	44.9	22.1	52.7
ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,	30.8	40	27.6	51.2
ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,	38.1	45.8	27.6	55.8
ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,	39.3	51.8	42.9	57.9
ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,	45.3	48.2	40.2	57.9
ACR20,wk28,n=115,103,na,na,33,35,21 ,21,86,17,19	47.8	65	9999	9999
ACR20,wk32,n=104,97,na,na,33,30,21, 19,87,17,17	56.7	61.9	9999	9999
ACR20,wk36,n=102,93,na,na,30,30,21, 20,85,18,16	56.9	53.8	9999	9999
ACR20,wk40,n=96,90,na,na,28,28,21,1 9,85,15,17	53.1	61.1	9999	9999
ACR20,wk44,n=97,90,na,na,28,27,20,1 8,84,15,16	56.7	61.1	9999	9999
ACR20,wk48,n=94,89,na,na,28,26,18,1 9,77,12,14	57.4	68.5	9999	9999
ACR20,wk52,n=92,88,na,na,28,26,20,1 8,79,15,15	56.5	62.5	9999	9999
ACR50,wk1,n=132,129,130,130,39,35,2 1,22,96,17,17	6.8	3.1	0.8	1.5
ACR50,wk2,n=131,130,134,134,39,36,2 3,22,99,17,18	5.3	9.2	3	3
ACR50,wk4,n=133,132,131,129,39,39,2 3,21,93,17,19	9.8	10.6	3.1	7.8
ACR50,wk8,n=132,127,131,131,39,39,2 3,22,95,17,19	9.1	16.5	10.7	20.6
ACR50,wk12,n=130,115,123,129,39,37, 23,21,94,17,18	10	15.7	11.4	24.8
ACR50,wk16,n=126,118,116,129,36,37, 21,22,94,16,19	15.9	23.7	11.2	26.4
ACR50,wk20,n=122,114,119,126,38,37, 23,21,91,16,19	15.6	21.9	12.6	31.7
ACR50,wk24,n=117,110,117,121,38,36, 21,22,87,16,18	14.5	22.7	14.5	33.1
ACR50,wk28,n=115,103,na,na,33,35,21 ,21,86,17,19	13.9	31.1	9999	9999
ACR50,wk32,n=104,97,na,na,33,30,21, 19,87,17,17	21.2	32	9999	9999
ACR50,wk36,n=102,93,na,na,30,30,21, 20,85,18,16	23.5	24.7	9999	9999
ACR50,wk40,n=96,90,na,na,28,28,21,1 9,85,15,17	25	25.6	9999	9999
ACR50,wk44,n=97,90,na,na,28,27,20,1 8,84,15,16	27.8	30	9999	9999
ACR50,wk48,n=94,89,na,na,28,26,18,1 9,77,12,14	25.5	42.7	9999	9999
ACR50,wk52,n=92,88,na,na,28,26,20,1 8,79,15,15	26.1	45.5	9999	9999
ACR70,wk1,n=132,129,130,130,39,35,2 1,22,96,17,17	0.8	0.8	0	0.8
ACR70,wk2,n=131,130,134,134,39,36,2 3,22,99,17,18	1.5	0.8	1.5	0.7

ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	4.5	3	1.5	1.6
ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	1.5	4.7	3.1	6.1
ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	3.1	3.5	3.3	10.9
ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	6.3	9.3	3.4	10
ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	6.6	8.8	6.7	11.1
ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	6	12.7	8.5	14.9
ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	6.1	17.5	9999	9999
ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	4.8	10	9999	9999
ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	5.9	11.8	9999	9999
ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	8.3	11.1	9999	9999
ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	12.4	18.9	9999	9999
ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	9.6	20.2	9999	9999
ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	6.5	19.3	9999	9999

End point values	Placebo non-responder - AIN457 75mg	Placebo non-responder - AIN457 150mg	Placebo responder - AIN457 75mg	Placebo responder - AIN457 150mg
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	39	39	23	22
Units: Percentage of participants number (not applicable)				
ACR20,wk1,n=132,129,130,130,39,35,21,22,96,1	5.1	5.7	14.3	13.6
ACR20,wk2,n=131,130,134,134,39,36,23,22,99,1	2.6	11.1	34.8	13.6
ACR20,wk4,n=133,132,131,129,39,39,23,21,93,1	15.4	12.8	43.5	42.9
ACR20,wk8,n=132,127,131,131,39,39,23,22,95,1	17.9	12.8	39.1	31.8
ACR20,wk12,n=130,115,123,129,39,37,23,21,94,	15.4	16.2	47.8	52.4
ACR20,wk16,n=126,118,116,129,36,37,21,22,94,	2.8	2.7	76.2	63.6
ACR20,wk20,n=122,114,119,126,38,37,23,21,91,	42.1	29.7	60.9	47.6
ACR20,wk24,n=117,110,117,121,38,36,21,22,87,	26.3	33.3	57.1	59.1
ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	33.3	37.1	71.4	90.5
ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	51.5	36.7	81	68.4
ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	46.7	56.7	85.7	65
ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	53.6	53.6	85.7	73.7

ACR20,wk44,n=97,90,na,na,28,27,20,1 8,84,15,16	50	55.6	85	77.8
ACR20,wk48,n=94,89,na,na,28,26,18,1 9,77,12,14	53.6	61.5	72.2	57.9
ACR20,wk52,n=92,88,na,na,28,26,20,1 8,79,15,15	39.3	57.7	75	88.9
ACR50,wk1,n=132,129,130,130,39,35,2 1,22,96,17,17	0	0	4.8	0
ACR50,wk2,n=131,130,134,134,39,36,2 3,22,99,17,18	0	0	13	4.5
ACR50,wk4,n=133,132,131,129,39,39,2 3,21,93,17,19	0	0	8.7	9.5
ACR50,wk8,n=132,127,131,131,39,39,2 3,22,95,17,19	5.1	5.1	34.8	9.1
ACR50,wk12,n=130,115,123,129,39,37, 23,21,94,17,18	2.6	8.1	21.7	23.8
ACR50,wk16,n=126,118,116,129,36,37, 21,22,94,16,19	0	0	38.1	22.7
ACR50,wk20,n=122,114,119,126,38,37, 23,21,91,16,19	7.9	2.7	34.8	14.3
ACR50,wk24,n=117,110,117,121,38,36, 21,22,87,16,18	0	11.1	38.1	22.7
ACR50,wk28,n=115,103,na,na,33,35,21 ,21,86,17,19	6.1	8.6	33.3	33.3
ACR50,wk32,n=104,97,na,na,33,30,21, 19,87,17,17	6.1	13.3	42.9	31.6
ACR50,wk36,n=102,93,na,na,30,30,21, 20,85,18,16	16.7	16.7	28.6	20
ACR50,wk40,n=96,90,na,na,28,28,21,1 9,85,15,17	14.3	28.6	38.1	26.3
ACR50,wk44,n=97,90,na,na,28,27,20,1 8,84,15,16	7.1	29.6	35	33.3
ACR50,wk48,n=94,89,na,na,28,26,18,1 9,77,12,14	14.3	23.1	38.9	26.3
ACR50,wk52,n=92,88,na,na,28,26,20,1 8,79,15,15	10.7	26.9	40	44.4
ACR70,wk1,n=132,129,130,130,39,35,2 1,22,96,17,17	0	0	0	0
ACR70,wk2,n=131,130,134,134,39,36,2 3,22,99,17,18	0	0	4.3	4.5
ACR70,wk4,n=133,132,131,129,39,39,2 3,21,93,17,19	0	0	4.3	4.8
ACR70,wk8,n=132,127,131,131,39,39,2 3,22,95,17,19	0	2.6	13	0
ACR70,wk12,n=130,115,123,129,39,37, 23,21,94,17,18	0	0	13	4.8
ACR70,wk16,n=126,118,116,129,36,37, 21,22,94,16,19	0	0	14.3	4.5
ACR70,wk20,n=122,114,119,126,38,37, 23,21,91,16,19	0	0	21.7	14.3
ACR70,wk24,n=117,110,117,121,38,36, 21,22,87,16,18	0	8.3	23.8	9.1
ACR70,wk28,n=115,103,na,na,33,35,21 ,21,86,17,19	0	2.9	14.3	14.3
ACR70,wk32,n=104,97,na,na,33,30,21, 19,87,17,17	0	3.3	19	0
ACR70,wk36,n=102,93,na,na,30,30,21, 20,85,18,16	3.3	0	23.8	0
ACR70,wk40,n=96,90,na,na,28,28,21,1 9,85,15,17	7.1	10.7	19	10.5
ACR70,wk44,n=97,90,na,na,28,27,20,1 8,84,15,16	0	11.1	25	11.1

ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	3.6	15.4	33.3	10.5
ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	0	7.7	30	16.7

End point values	Abatacept responders	Abatacept non-responders - AIN457 75mg	Abatacept non-responders - AIN457 150mg	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	101	18	19	
Units: Percentage of participants				
number (not applicable)				
ACR20,wk1,n=132,129,130,130,39,35,21,22,96,1	14.6	0	5.9	
ACR20,wk2,n=131,130,134,134,39,36,23,22,99,1	29.3	11.8	16.7	
ACR20,wk4,n=133,132,131,129,39,39,23,21,93,1	41.9	17.6	10.5	
ACR20,wk8,n=132,127,131,131,39,39,23,22,95,1	61.1	29.4	31.6	
ACR20,wk12,n=130,115,123,129,39,37,23,21,94,	62.8	17.6	22.2	
ACR20,wk16,n=126,118,116,129,36,37,21,22,94,	76.6	0	0	
ACR20,wk20,n=122,114,119,126,38,37,23,21,91,	73.6	6.3	26.3	
ACR20,wk24,n=117,110,117,121,38,36,21,22,87,	69	31.3	27.8	
ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	74.4	41.2	42.1	
ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	74.7	23.5	47.1	
ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	77.6	27.8	56.3	
ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	71.8	40	58.8	
ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16	77.4	33.3	31.3	
ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14	71.4	25	50	
ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15	74.7	40	33.3	
ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17	1	0	5.9	
ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18	3	0	5.6	
ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19	10.8	0	0	
ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19	25.3	11.8	5.3	
ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18	30.9	5.9	11.1	
ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19	36.2	0	0	
ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19	40.7	0	15.8	
ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18	44.8	0	5.6	

ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19	41.9	23.5	0	
ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17	47.1	5.9	0	
ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16	47.1	16.7	18.8	
ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17	45.9	20	5.9	
ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16	50	13.3	6.3	
ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14	48.1	0	0	
ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15	51.9	20	13.3	
ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17	1	0	0	
ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18	1	0	0	
ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	2.2	0	0	
ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	7.4	5.9	0	
ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	14.9	0	0	
ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	13.8	0	0	
ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	15.4	0	0	
ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	19.5	0	5.6	
ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	17.4	5.9	0	
ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	21.8	0	0	
ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	23.5	11.1	0	
ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	21.2	13.3	0	
ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	26.2	6.7	0	
ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	27.3	0	0	
ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	22.8	13.3	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in HAQ-DI - using mixed model repeated measures (MMRM)

End point title	Change from baseline in HAQ-DI - using mixed model repeated measures (MMRM)
-----------------	---

End point description:

The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past

week, "are you able to..." perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.

End point type	Secondary
End point timeframe:	
baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24	

End point values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	138	138
Units: score on a scale				
least squares mean (standard error)				
week 1, n=132,129,130,129	-0.22 (± 0.032)	-0.21 (± 0.032)	-0.08 (± 0.032)	-0.19 (± 0.032)
week 2, n=131,130,134,133	-0.22 (± 0.036)	-0.25 (± 0.036)	-0.16 (± 0.036)	-0.26 (± 0.036)
week 4, n=133,133,131,130	-0.3 (± 0.039)	-0.31 (± 0.04)	-0.17 (± 0.04)	-0.36 (± 0.04)
week 8, n=132,127,131,130	-0.29 (± 0.042)	-0.32 (± 0.043)	-0.17 (± 0.043)	-0.46 (± 0.043)
week 12, n=130,114,123,129	-0.31 (± 0.046)	-0.33 (± 0.047)	-0.18 (± 0.047)	-0.51 (± 0.046)
week 16, n=127,118,116,129	-0.3 (± 0.048)	-0.37 (± 0.049)	-0.22 (± 0.049)	-0.52 (± 0.048)
week 20, n=122,114,47,92	-0.36 (± 0.051)	-0.42 (± 0.052)	-0.21 (± 0.066)	-0.57 (± 0.054)
week 24, n=117,110,44,86	-0.3 (± 0.049)	-0.39 (± 0.051)	-0.26 (± 0.065)	-0.61 (± 0.053)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in HAQ-DI - observed data

End point title	Change from baseline in HAQ-DI - observed data
End point description:	
<p>The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, "are you able to..." perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement. The HAQ-DI results from baseline up to week 52 were based on observed data, i.e. without imputation.</p>	
End point type	Secondary
End point timeframe:	
baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52	

End point values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	138	138
Units: score on a scale				
arithmetic mean (standard deviation)				
wk1,n=132,129,130,129,39,35,21,22,9 5,17,17	-0.225 (± 0.3766)	-0.215 (± 0.4095)	-0.101 (± 0.3186)	-0.194 (± 0.429)
Wk2,n=131,130,134,133,39,36,23,22,1 33,98,17,18	-0.215 (± 0.3877)	-0.239 (± 0.4885)	-0.191 (± 0.434)	-0.254 (± 0.452)
Wk4,n=133,133,131,130,39,39,23,21,9 4,17,19	-0.299 (± 0.4551)	-0.3 (± 0.5184)	-0.214 (± 0.4492)	-0.368 (± 0.513)
Wk8,n=132,127,131,130,39,39,23,22,9 4,17,19	-0.277 (± 0.5062)	-0.309 (± 0.5175)	-0.217 (± 0.5457)	-0.463 (± 0.5182)
wk12,n=130,114,123,129,39,37,23,21, 94,17,18	-0.287 (± 0.5384)	-0.307 (± 0.5488)	-0.241 (± 0.5152)	-0.508 (± 0.6369)
Wk16,n=127,118,116,129,36,37,21,22, 94,16,19	-0.294 (± 0.5236)	-0.355 (± 0.6217)	-0.279 (± 0.5493)	-0.535 (± 0.6418)
Wk20,n=122,114,119,125,38,37,23,21, 90,16,19	-0.333 (± 0.5111)	-0.402 (± 0.6429)	-0.319 (± 0.5637)	-0.583 (± 0.6654)
Wk24,n=117,110,117,120,38,36,21,22, 86,16,18	-0.268 (± 0.493)	-0.405 (± 0.5767)	0.346 (± 0.5941)	-0.59 (± 0.6872)
Wk28,n=115,102,na,na,33,35,21,21,86, 17,19	-0.304 (± 0.5342)	-0.439 (± 0.578)	9999 (± 9999)	9999 (± 9999)
Wk32,n=104,97,na,na,33,30,21,19,87,1 7,17	-0.358 (± 0.4964)	-0.505 (± 0.5759)	9999 (± 9999)	9999 (± 9999)
Wk36,n=102,93,na,na,30,30,21,19,84,1 8,16,	-0.339 (± 0.5687)	-0.43 (± 0.5573)	9999 (± 9999)	9999 (± 9999)
Wk40,n=96,89,na,na,28,28,21,19,84,15 ,17	-0.424 (± 0.5967)	-0.44 (± 0.5416)	9999 (± 9999)	9999 (± 9999)
Wk44,n=97,90,na,na,28,27,20,18,84,15 ,16	-0.331 (± 0.5871)	-0.449 (± 0.5427)	9999 (± 9999)	9999 (± 9999)
Wk48,n- 94,89,na,na,28,26,19,19,76,12,14	-0.303 (± 0.5062)	-0.483 (± 0.5459)	9999 (± 9999)	9999 (± 9999)
Wk52,n=92,87,na,na,28,26,20,18,79,15 ,15	-0.341 (± 0.5428)	-0.516 (± 0.6036)	9999 (± 9999)	9999 (± 9999)

End point values	Placebo non- responder - AIN457 75mg	Placebo non- responder - AIN457 150mg	Placebo responder - AIN457 75mg	Placebo responder - AIN457 150mg
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	39	39	23	22
Units: score on a scale				
arithmetic mean (standard deviation)				
wk1,n=132,129,130,129,39,35,21,22,9 5,17,17	-0.119 (± 0.2896)	-0.079 (± 0.3093)	-0.125 (± 0.4257)	-0.153 (± 0.2468)
Wk2,n=131,130,134,133,39,36,23,22,1 33,98,17,18	-0.122 (± 0.2605)	-0.176 (± 0.4631)	-0.38 (± 0.5063)	-0.25 (± 0.5015)
Wk4,n=133,133,131,130,39,39,23,21,9 4,17,19	-0.077 (± 0.3634)	-0.224 (± 0.4968)	-0.364 (± 0.5627)	-0.31 (± 0.3103)
Wk8,n=132,127,131,130,39,39,23,22,9 4,17,19	-0.186 (± 0.5097)	-0.128 (± 0.5077)	-0.543 (± 0.6313)	-0.176 (± 0.4782)

wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.109 (± 0.4783)	-0.179 (± 0.5133)	-0.451 (± 0.6167)	-0.381 (± 0.3982)
Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.167 (± 0.5295)	-0.111 (± 0.4591)	-0.565 (± 0.5356)	-0.472 (± 0.5988)
Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.237 (± 0.4756)	-0.179 (± 0.5158)	-0.543 (± 0.5325)	-0.47 (± 0.7309)
Wk24,n=117,110,117,120,38,36,21,22,86,16,18	-0.257 (± 0.473)	-0.253 (± 0.6502)	-0.589 (± 0.5648)	-0.42 (± 0.6732)
Wk28,n=115,102,na,na,33,35,21,21,86,17,19	-0.345 (± 0.588)	-0.336 (± 0.5846)	-0.625 (± 0.4809)	-0.601 (± 0.5571)
Wk32,n=104,97,na,na,33,30,21,19,87,17,17	-0.284 (± 0.4627)	-0.3 (± 0.5039)	-0.679 (± 0.5414)	-0.546 (± 0.5998)
Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	-0.368 (± 0.5397)	-0.383 (± 0.45)	-0.607 (± 0.5538)	-0.474 (± 0.6032)
Wk40,n=96,89,na,na,28,28,21,19,84,15,17	-0.522 (± 0.6805)	-0.391 (± 0.5446)	-0.571 (± 0.5736)	-0.539 (± 0.6998)
Wk44,n=97,90,na,na,28,27,20,18,84,15,16	-0.277 (± 0.6377)	-0.523 (± 0.6587)	-0.638 (± 0.5144)	-0.514 (± 0.7752)
Wk48,n-94,89,na,na,28,26,19,19,76,12,14	-0.348 (± 0.5886)	-0.413 (± 0.5698)	-0.605 (± 0.6113)	-0.454 (± 0.5547)
Wk52,n=92,87,na,na,28,26,20,18,79,15,15	-0.402 (± 0.5436)	-0.351 (± 0.6335)	-0.606 (± 0.6492)	-0.569 (± 0.7126)

End point values	Abatacept responders	Abatacept non-responders - AIN457 75mg	Abatacept non-responders - AIN457 150mg	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	101	18	19	
Units: score on a scale				
arithmetic mean (standard deviation)				
wk1,n=132,129,130,129,39,35,21,22,95,17,17	-0.232 (± 0.4551)	-0.081 (± 0.3616)	-0.096 (± 0.3047)	
Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18	-0.3 (± 0.4693)	-0.132 (± 0.363)	-0.118 (± 0.3987)	
Wk4,n=133,133,131,130,39,39,23,21,94,17,19	-0.445 (± 0.5245)	-0.11 (± 0.3505)	-0.217 (± 0.4874)	
Wk8,n=132,127,131,130,39,39,23,22,94,17,19	-0.543 (± 0.5289)	-0.206 (± 0.49)	-0.303 (± 0.378)	
wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.622 (± 0.652)	-0.221 (± 0.4274)	-0.181 (± 0.5376)	
Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.66 (± 0.659)	-0.195 (± 0.4281)	-0.204 (± 0.4827)	
Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.699 (± 0.6849)	-0.086 (± 0.3972)	-0.454 (± 0.5436)	
Wk24,n=117,110,117,120,38,36,21,22,86,16,18	-0.744 (± 0.6787)	-0.18 (± 0.4257)	-0.215 (± 0.6443)	
Wk28,n=115,102,na,na,33,35,21,21,86,17,19	-0.689 (± 0.6428)	-0.309 (± 0.5522)	-0.303 (± 0.5882)	
Wk32,n=104,97,na,na,33,30,21,19,87,17,17	-0.741 (± 0.6909)	-0.228 (± 0.5612)	-0.375 (± 0.7315)	
Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	-0.756 (± 0.6844)	-0.285 (± 0.5891)	-0.43 (± 0.6723)	
Wk40,n=96,89,na,na,28,28,21,19,84,15,17	-0.763 (± 0.675)	-0.242 (± 0.6312)	-0.39 (± 0.6523)	
Wk44,n=97,90,na,na,28,27,20,18,84,15,16	-0.781 (± 0.7252)	-0.308 (± 0.6319)	-0.203 (± 0.7917)	
Wk48,n-94,89,na,na,28,26,19,19,76,12,14	-0.798 (± 0.6481)	-0.229 (± 0.6546)	-0.286 (± 0.7618)	

Wk52, n=92,87,na,na,28,26,20,18,79,15,15	-0.788 (± 0.6853)	-0.392 (± 0.5216)	-0.258 (± 0.8298)	
--	-------------------	-------------------	-------------------	--

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Disease Activity Score utilizing CRP (DAS28-CRP) - using MMRM

End point title	Change from baseline in Disease Activity Score utilizing CRP (DAS28-CRP) - using MMRM
End point description:	The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement.
End point type	Secondary
End point timeframe:	baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24

End point values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	138	39
Units: score on a scale				
least squares mean (standard error)				
week 1, n=131,129,130,129	-0.89 (± 0.069)	-0.73 (± 0.069)	-0.22 (± 0.069)	-0.5 (± 0.069)
week 2, n=131,127,132,133	-0.96 (± 0.08)	-0.9 (± 0.081)	-0.35 (± 0.08)	-0.78 (± 0.08)
week 4, n=130,131,138,138	-1.2 (± 0.09)	-1.11 (± 0.09)	-0.48 (± 0.09)	-1.11 (± 0.091)
week 8, n=130,126,130,130	-1.21 (± 0.093)	-1.23 (± 0.094)	-0.61 (± 0.093)	-1.55 (± 0.093)
week 12, n=130,114,123,128	-1.23 (± 0.097)	-1.36 (± 0.102)	-0.73 (± 0.1)	-1.78 (± 0.098)
week 16, n=126,116,114,127	-1.23 (± 0.108)	-1.4 (± 0.112)	-0.57 (± 0.112)	-1.71 (± 0.108)
week 20, n=121,114,47,92	-1.44 (± 0.108)	-1.49 (± 0.111)	-0.89 (± 0.146)	-1.96 (± 0.117)
week 24, n=116,108,44,84	-1.47 (± 0.115)	-1.47 (± 0.119)	-1.02 (± 0.163)	-2.07 (± 0.128)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Disease Activity Score utilizing CRP (DAS28-CRP) - observed data

End point title	Change from baseline in Disease Activity Score utilizing CRP (DAS28-CRP) - observed data
End point description: The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement. The DAS28-CRP results from baseline up to week 52 were based on observed data, i.e. without imputation.	
End point type	Secondary
End point timeframe: baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52	

End point values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	138	138
Units: score on a scale				
arithmetic mean (standard deviation)				
Wk1,n=131,129,130,129,39,35,21,22,95,17,17	-0.886 (± 0.9784)	-0.759 (± 0.8654)	-0.211 (± 0.6877)	-0.502 (± 0.7539)
Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.909 (± 1.0331)	-0.9 (± 1.0284)	-0.363 (± 0.8388)	-0.755 (± 0.9234)
Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-1.163 (± 1.1656)	-1.15 (± 1.1942)	-0.492 (± 0.8876)	-1.095 (± 1.0483)
Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-1.181 (± 1.1821)	-1.283 (± 1.1678)	-0.644 (± 1.1356)	-1.541 (± 1.1172)
Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-1.229 (± 1.1782)	-1.402 (± 1.2182)	-0.742 (± 1.233)	-1.79 (± 1.2356)
Wk16,n=126,116,114,128,36,36,21,21,94,15,19	-1.225 (± 1.2866)	-1.455 (± 1.3489)	-0.592 (± 1.2557)	-1.691 (± 1.2979)
Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-1.427 (± 1.3266)	-1.569 (± 1.2361)	-1.164 (± 1.2087)	-1.84 (± 1.4144)
Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-1.467 (± 1.3116)	-1.579 (± 1.3221)	-1.248 (± 1.2915)	-1.989 (± 1.4717)
Wk28,n=115,103,na,na,33,35,21,21,86,17,18	-1.484 (± 1.3216)	-1.819 (± 1.3434)	9999 (± 9999)	9999 (± 9999)
Wk32,n=103,97,na,na,33,39,23,22,87,17,16	-1.738 (± 1.2783)	-1.966 (± 1.177)	9999 (± 9999)	9999 (± 9999)
Wk36,n=101,92,na,na,30,30,21,20,84,18,15	-1.737 (± 1.4592)	-1.82 (± 1.25)	9999 (± 9999)	9999 (± 9999)
Wk40,n=96,90,na,na,28,28,21,19,84,15,17	-1.742 (± 1.3259)	-1.788 (± 1.1333)	9999 (± 9999)	9999 (± 9999)
Wk44,n=96,88,na,na,28,27,20,18,84,15,16	-1.764 (± 1.3227)	-1.932 (± 1.285)	9999 (± 9999)	9999 (± 9999)
Wk48,n=94,88,na,na,28,26,18,19,76,12,14	-1.761 (± 1.3152)	-2.2 (± 1.3293)	9999 (± 9999)	9999 (± 9999)
Wk52,n=92,86,na,na,28,26,20,18,79,15,15	-1.839 (± 1.3755)	-2.109 (± 1.4)	9999 (± 9999)	9999 (± 9999)

End point values	Placebo non-	Placebo non-	Placebo	Placebo
------------------	--------------	--------------	---------	---------

	responder - AIN457 75mg	responder - AIN457 150mg	responder - AIN457 75mg	responder - AIN457 150mg
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	39	39	23	22
Units: score on a scale				
arithmetic mean (standard deviation)				
Wk1,n=131,129,130,129,39,35,21,22,95,17,17	-0.147 (± 0.5527)	-0.141 (± 0.7095)	-0.572 (± 0.7856)	-0.235 (± 0.7699)
Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.191 (± 0.7331)	-0.368 (± 0.717)	-0.835 (± 0.9466)	-0.292 (± 0.7448)
Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-0.252 (± 0.8116)	-0.352 (± 0.7471)	-1.034 (± 0.9119)	-0.767 (± 0.9661)
Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-0.546 (± 1.1597)	-0.312 (± 0.9151)	-1.403 (± 1.206)	-0.613 (± 0.9772)
Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-0.311 (± 0.9514)	-0.383 (± 1.1765)	-1.588 (± 0.9714)	-1.33 (± 1.4721)
Wk16,n=126,116,114,128,36,36,21,21,94,15,19	0.128 (± 0.8579)	0.045 (± 0.9145)	-2.008 (± 0.8675)	-1.503 (± 0.8746)
Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-0.683 (± 1.1231)	-0.937 (± 1.0966)	-2.108 (± 1.0368)	-1.399 (± 1.1487)
Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-0.666 (± 0.9983)	-1.14 (± 1.1954)	-2.343 (± 1.2649)	-1.362 (± 1.2999)
Wk28,n=115,103,na,na,33,35,21,21,86,17,18	-1.172 (± 1.1602)	-1.244 (± 1.2433)	-2.117 (± 0.8573)	-1.782 (± 1.0655)
Wk32,n=103,97,na,na,33,39,23,22,87,17,16	-1.408 (± 1.3855)	-1.475 (± 1.1846)	-2.363 (± 1.0711)	-1.875 (± 0.9807)
Wk36,n=101,92,na,na,30,30,21,20,84,18,15	-1.271 (± 1.4949)	-1.444 (± 1.1949)	-2.269 (± 1.0688)	-1.784 (± 0.9029)
Wk40,n=96,90,na,na,28,28,21,19,84,15,17	-1.354 (± 1.359)	-1.494 (± 1.3243)	-2.315 (± 1.0773)	-2.134 (± 1.0405)
Wk44,n=96,88,na,na,28,27,20,18,84,15,16	-1.168 (± 1.2638)	-1.858 (± 1.2373)	-2.155 (± 0.9488)	-2.121 (± 1.1347)
Wk48,n=94,88,na,na,28,26,18,19,76,12,14	-1.516 (± 1.0635)	-1.66 (± 1.1805)	-2.259 (± 1.1813)	-1.964 (± 1.3404)
Wk52,n=92,86,na,na,28,26,20,18,79,15,15	-1.487 (± 1.0729)	-1.69 (± 1.2093)	-2.07 (± 0.9984)	-2.334 (± 1.1428)

End point values	Abatacept responders	Abatacept non-responders - AIN457 75mg	Abatacept non-responders - AIN457 150mg	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	101	18	19	
Units: score on a scale				
arithmetic mean (standard deviation)				
Wk1,n=131,129,130,129,39,35,21,22,95,17,17	-0.577 (± 0.7924)	-0.361 (± 0.3578)	-0.222 (± 0.7695)	
Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.755 (± 0.9234)	-0.882 (± 0.9526)	-0.359 (± 0.898)	
Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-1.268 (± 1.0533)	-0.595 (± 1.116)	-0.706 (± 0.6999)	
Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-1.816 (± 1.0708)	-0.834 (± 1.1469)	-0.808 (± 0.6444)	
Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-2.144 (± 1.1028)	-0.749 (± 1.0757)	-0.945 (± 1.1008)	
Wk16,n=126,116,114,128,36,36,21,21,94,15,19	-2.159 (± 1.0767)	-0.49 (± 0.817)	-0.322 (± 1.0262)	

Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-2.317 (± 1.2549)	-0.402 (± 0.982)	-0.792 (± 1.0272)
Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-2.435 (± 1.3266)	-0.772 (± 1.1656)	-0.923 (± 1.256)
Wk28,n=115,103,na,na,33,35,21,21,86,17,18	-2.47 (± 1.2153)	-1.137 (± 1.205)	-0.973 (± 1.1034)
Wk32,n=103,97,na,na,33,39,23,22,87,17,16	-2.629 (± 1.3104)	-0.961 (± 1.0043)	-1.464 (± 1.2025)
Wk36,n=101,92,na,na,30,30,21,20,84,18,15	-2.642 (± 1.4305)	-1.2 (± 1.3228)	-1.425 (± 0.9247)
Wk40,n=96,90,na,na,28,28,21,19,84,15,17	-2.549 (± 1.3305)	-1.201 (± 1.5293)	-1.612 (± 1.1839)
Wk44,n=96,88,na,na,28,27,20,18,84,15,16	-2.697 (± 1.2117)	-0.881 (± 1.3337)	-1.528 (± 1.2973)
Wk48,n=94,88,na,na,28,26,18,19,76,12,14	-2.634 (± 1.2189)	-1.013 (± 1.1738)	-1.4 (± 1.1985)
Wk52,n=92,86,na,na,28,26,20,18,79,15,15	-2.676 (± 1.3593)	-1.39 (± 1.1884)	-0.982 (± 1.1943)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in hsCRP - observed data

End point title	Change from baseline in hsCRP - observed data
End point description:	
Blood samples were obtained to identify the presence of inflammation, to determine its severity and to monitor response to treatment. A negative change from baseline indicates improvement. The hsCRP results from baseline up to week 52 were based on observed data, i.e. without imputation.	
End point type	Secondary
End point timeframe:	
baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52	

End point values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	138	138
Units: mg/L				
arithmetic mean (standard deviation)				
Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-10.91 (± 30.815)	-10.31 (± 27.754)	-0.69 (± 15.521)	-5.64 (± 18.55)
Wk2,n=133,129,133,135,39,36,23,21,100,17,18	-10.24 (± 33.209)	-11.51 (± 32.139)	-2.21 (± 14.501)	-6.36 (± 19.416)
Wk4,n=131,134,129,133,39,38,23,21,97,17,19	-9.1 (± 20.514)	-10.76 (± 33.376)	-1.53 (± 19.311)	-6.7 (± 20.732)
Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-10.18 (± 33.4)	-12.94 (± 30.854)	-2.94 (± 20.601)	-8.48 (± 21.134)
Wk12,n=133,119,128,131,39,39,23,22,96,17,18	-9.41 (± 31.859)	-9.66 (± 24.298)	-0.69 (± 18.908)	-9.72 (± 25.787)
Wk16,n=129,120,121,131,36,38,21,21,96,16,19	-9.97 (± 33.291)	-5.78 (± 25.418)	-1.82 (± 20.849)	-8.37 (± 22.571)

Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-9.19 (± 32.876)	-8.05 (± 22.394)	-3.75 (± 29.301)	-9.43 (± 23.212)
Wk24,n=121,113,116,120,37,36,21,22,86,16,18	-6.9 (± 22.098)	-4.92 (± 23.075)	-6.88 (± 21.014)	-8.66 (± 21.574)
Wk28,n=119,110,na,na,34,35,21,21,89,17,18	-4.94 (± 23.155)	-5.87 (± 25.885)	9999 (± 9999)	9999 (± 9999)
Wk32,n=107,101,na,na,34,32,20,21,87,17,16	-8.57 (± 20.826)	7.37 (± 24.564)	9999 (± 9999)	9999 (± 9999)
Wk36,n=107,98,na,na,32,31,21,20,85,18,15	-6.6 (± 25.895)	-6.36 (± 22.571)	9999 (± 9999)	9999 (± 9999)
Wk40,n=101,96,na,na,29,29,22,20,86,15,17	-8.74 (± 22.257)	-7.09 (± 24.325)	9999 (± 9999)	9999 (± 9999)
Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	-6.59 (± 20.975)	-7.25 (± 24.681)	9999 (± 9999)	9999 (± 9999)
Wk48,n=97,91,na,na,28,29,20,19,79,13,14	-6.19 (± 18.912)	-7.63 (± 21.682)	9999 (± 9999)	9999 (± 9999)
Wk52,n=95,92,na,na,29,28,20,18,83,16,16	-6.68 (± 26.24)	-8.14 (± 22.149)	9999 (± 9999)	9999 (± 9999)

End point values	Placebo non-responder - AIN457 75mg	Placebo non-responder - AIN457 150mg	Placebo responder - AIN457 75mg	Placebo responder - AIN457 150mg
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	39	39	23	22
Units: mg/L				
arithmetic mean (standard deviation)				
Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-0.33 (± 10.43)	-0.84 (± 24.777)	-0.4 (± 12.244)	-1.5 (± 7.541)
Wk2,n=133,129,133,135,39,36,23,21,100,17,18	0.43 (± 15.333)	-5.48 (± 17.301)	-1.7 (± 11.17)	-4.78 (± 10.515)
Wk4,n=131,134,129,133,39,38,23,21,97,17,19	2.23 (± 23.317)	-1.94 (± 21.927)	-6.47 (± 12.458)	-1.95 (± 12.09)
Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-4.72 (± 18.766)	-3.28 (± 25.501)	0.13 (± 18.061)	-1.5 (± 12.839)
Wk12,n=133,119,128,131,39,39,23,22,96,17,18	2.11 (± 18.312)	-2.89 (± 20.763)	-2.74 (± 12.899)	2.1 (± 22.545)
Wk16,n=129,120,121,131,36,38,21,21,96,16,19	3.92 (± 23.403)	-2.13 (± 24.422)	-5.67 (± 9.583)	-4.29 (± 13.497)
Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-5.33 (± 20.645)	-7.77 (± 27.581)	3.23 (± 48.634)	-1.06 (± 15.737)
Wk24,n=121,113,116,120,37,36,21,22,86,16,18	-7.06 (± 20.298)	-11.46 (± 26.373)	-6.4 (± 11.562)	0.45 (± 18.244)
Wk28,n=119,110,na,na,34,35,21,21,89,17,18	-4.43 (± 21.777)	-11.1 (± 27.186)	-7.97 (± 18.018)	0.09 (± 24.933)
Wk32,n=107,101,na,na,34,32,20,21,87,17,16	-4.34 (± 23.742)	-9.08 (± 25.867)	-5.02 (± 10.3)	-5.51 (± 14.279)
Wk36,n=107,98,na,na,32,31,21,20,85,18,15	-4.21 (± 27.424)	-2.35 (± 37.226)	-2.73 (± 21.272)	-6.78 (± 13.94)
Wk40,n=101,96,na,na,29,29,22,20,86,15,17	-7.07 (± 26.156)	2.39 (± 32.966)	-4.46 (± 22.808)	-4.73 (± 13.502)
Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	-6.66 (± 23.396)	-8.53 (± 19.97)	-6.5 (± 19.968)	-7.27 (± 13.887)
Wk48,n=97,91,na,na,28,29,20,19,79,13,14	-10.49 (± 25.564)	-4.76 (± 15.784)	-1.43 (± 33.122)	-6.97 (± 13.68)
Wk52,n=95,92,na,na,29,28,20,18,83,16,16	-4.63 (± 25.795)	-4.79 (± 22.882)	2.95 (± 9.88)	-4.88 (± 11.707)

End point values	Abatacept responders	Abatacept non-responders - AIN457 75mg	Abatacept non-responders - AIN457 150mg	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	101	18	19	
Units: mg/L				
arithmetic mean (standard deviation)				
Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-6.4 (± 20.458)	-2.92 (± 12.405)	-4.07 (± 10.811)	
Wk2,n=133,129,133,135,39,36,23,21,100,17,18	-7.52 (± 20.301)	-3.84 (± 13.737)	-2.3 (± 19.035)	
Wk4,n=131,134,129,133,39,38,23,21,97,17,19	-7.53 (± 22.982)	-4.42 (± 14.991)	-4.5 (± 11.029)	
Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-10.13 (± 22.724)	-0.54 (± 14.849)	-4.59 (± 16.603)	
Wk12,n=133,119,128,131,39,39,23,22,96,17,18	-12.17 (± 25.813)	-4.18 (± 16.024)	-1.94 (± 31.483)	
Wk16,n=129,120,121,131,36,38,21,21,96,16,19	-11.25 (± 23.692)	-1.41 (± 8.81)	0.32 (± 22.024)	
Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-11.59 (± 24.271)	-3.94 (± 15.716)	-3.99 (± 32.871)	
Wk24,n=121,113,116,120,37,36,21,22,86,16,18	-11.72 (± 22.198)	-4.94 (± 13.605)	2.63 (± 20.875)	
Wk28,n=119,110,na,na,34,35,21,21,89,17,18	-12.08 (± 22.791)	-4.51 (± 14.144)	-1.7 (± 22.671)	
Wk32,n=107,101,na,na,34,32,20,21,87,17,16	-12.83 (± 23.33)	-4.26 (± 15.329)	-7.14 (± 17.446)	
Wk36,n=107,98,na,na,32,31,21,20,85,18,15	-12.19 (± 24.535)	-4.38 (± 14.479)	-0.47 (± 27.932)	
Wk40,n=101,96,na,na,29,29,22,20,86,15,17	-12.63 (± 23.788)	-2.75 (± 17.297)	-7.95 (± 18.343)	
Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	-12.32 (± 25.47)	-1.33 (± 4.846)	-3.69 (± 24.389)	
Wk48,n=97,91,na,na,28,29,20,19,79,13,14	-13.9 (± 25.636)	-3.5 (± 21.343)	-4.48 (± 16.918)	
Wk52,n=95,92,na,na,29,28,20,18,83,16,16	-11.19 (± 27.768)	-6.73 (± 14.972)	-5.78 (± 18.534)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Erythrocyte Sedimentation Rate (ESR) - observed data

End point title	Change from baseline in Erythrocyte Sedimentation Rate (ESR) - observed data
-----------------	--

End point description:

Blood samples were obtained to monitor disease activity and response to treatment. A negative change from baseline indicates improvement. The ESR results from baseline up to week 52 were based on observed data, i.e. without imputation.

End point type	Secondary
----------------	-----------

End point timeframe:

baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

End point values	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	138	138
Units: mm/hr				
arithmetic mean (standard deviation)				
Wk1,n=133,130,131,131,39,36,21,22,9 7,17,17,	-7.5 (± 18.74)	-8.4 (± 19.2)	-5.7 (± 15.68)	-9.5 (± 16.55)
Wk2,n=133,130,135,134,39,36,23,22,9 9,17,18	-12.2 (± 19.06)	-10.5 (± 19.05)	-5.7 (± 18.22)	-11 (± 19.5)
Wk4,n=133,135,131,133,39,39,23,21,9 7,17,19	-12.7 (± 22.23)	-12.1 (± 21.88)	-6 (± 18.9)	-12.6 (± 18.14)
Wk8,n=133,129,131,132,39,39,23,22,9 6,17,19	-15.4 (± 20.38)	-15.7 (± 21.62)	-6.4 (± 22.72)	-17.6 (± 20.89)
Wk12,n=133,118,127,131,39,39,23,21, 96,17,18	-14.7 (± 20.08)	-18.4 (± 21.18)	-5.8 (± 21.02)	-19.4 (± 20.97)
Wk16,n=129,121,122,130,36,38,21,22, 95,16,19	-16.2 (± 21.22)	-15.6 (± 19.09)	-6.5 (± 23.48)	-18.5 (± 24.32)
Wk20,n=123,116,120,127,38,37,23,21, 91,17,19	-16.3 (± 20.9)	-17.7 (± 19.9)	-9.1 (± 26.29)	-21.1 (± 23.66)
Wk24,n=122,113,117,123,38,36,21,22, 88,17,18	-13.9 (± 23.65)	-16 (± 20.2)	-12 (± 24.31)	-19.6 (± 24.52)
Wk28,n=119,110,na,na,34,35,21,21,89, 17,19	-15.4 (± 22.95)	-16.8 (± 23.05)	9999 (± 9999)	9999 (± 9999)
Wk32,n=108,101,na,na,34,32,21,21,88, 17,16	-18.3 (± 23.51)	-17.4 (± 21.57)	9999 (± 9999)	9999 (± 9999)
Wk36,n=107,98,na,na,32,31,21,20,87,1 8,16	-16.6 (± 25.2)	-18.4 (± 21.51)	9999 (± 9999)	9999 (± 9999)
Wk40,n=101,96,na,na,29,29,22,20,85,1 5,17	-18.1 (± 21.06)	-17.3 (± 21.05)	9999 (± 9999)	9999 (± 9999)
Wk44,n=98,93,na,na,28,28,20,19,85,15 ,16	-18 (± 21.08)	-16.7 (± 23.87)	9999 (± 9999)	9999 (± 9999)
Wk48,n=97,92,na,na,28,30,20,19,79,13 ,14	-17.8 (± 23.11)	-19.8 (± 20.3)	9999 (± 9999)	9999 (± 9999)
Wk52,n=94,91,na,na,29,28,20,18,83,16 ,16	-17.7 (± 21.08)	-20.6 (± 23.48)	9999 (± 9999)	9999 (± 9999)

End point values	Placebo non- responder - AIN457 75mg	Placebo non- responder - AIN457 150mg	Placebo responder - AIN457 75mg	Placebo responder - AIN457 150mg
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	39	39	23	22
Units: mm/hr				
arithmetic mean (standard deviation)				
Wk1,n=133,130,131,131,39,36,21,22,9 7,17,17,	-8.4 (± 12.65)	-1.1 (± 18.88)	-5.7 (± 14.97)	-7.1 (± 13.22)
Wk2,n=133,130,135,134,39,36,23,22,9 9,17,18	-4 (± 12.69)	-5.6 (± 26.44)	-9.7 (± 17.86)	-6.6 (± 14.44)

Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-3.7 (± 14.35)	-3.8 (± 20.5)	-9.3 (± 13.81)	-8.2 (± 23.89)
Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-9.4 (± 19.24)	-0.9 (± 27.25)	-8.2 (± 24.09)	-8.3 (± 14.29)
Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-5.9 (± 17.96)	-1.5 (± 25.62)	-11.2 (± 18.06)	-5.5 (± 20.06)
Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-3.1 (± 19.21)	-1.1 (± 25.47)	-17.6 (± 23.03)	-4.9 (± 20.54)
Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-21.1 (± 23.66)	-10.5 (± 20.08)	-7.4 (± 29.4)	-11.6 (± 34.23)
Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-10.8 (± 20.33)	-14.7 (± 27.77)	-16.1 (± 21.57)	-5.5 (± 27.07)
Wk28,n=119,110,na,na,34,35,21,21,89,17,19	-17.9 (± 24.87)	-12.5 (± 30.87)	-12.3 (± 24.1)	-14.6 (± 17.31)
Wk32,n=108,101,na,na,34,32,21,21,88,17,16	-17.2 (± 16.7)	-12.8 (± 26.21)	-16.8 (± 24.37)	-14.1 (± 20.72)
Wk36,n=107,98,na,na,32,31,21,20,87,18,16	-17.8 (± 21.72)	-13.4 (± 29.49)	-17.3 (± 22.02)	-16.5 (± 17.95)
Wk40,n=101,96,na,na,29,29,22,20,85,15,17	-20.6 (± 19.66)	-12.3 (± 26.37)	-13.3 (± 18.78)	-16.4 (± 21.79)
Wk44,n=98,93,na,na,28,28,20,19,85,15,16	-20.1 (± 17.61)	-16 (± 25.3)	-12 (± 29.2)	-19.2 (± 22.57)
Wk48,n=97,92,na,na,28,30,20,19,79,13,14	-20.8 (± 18.26)	-7.2 (± 22.58)	-12.2 (± 29.55)	-19.4 (± 20.58)
Wk52,n=94,91,na,na,29,28,20,18,83,16,16	-14.9 (± 20.53)	-15.1 (± 21.5)	-14.4 (± 24.54)	-13.6 (± 27.16)

End point values	Abatacept responders	Abatacept non-responders - AIN457 75mg	Abatacept non-responders - AIN457 150mg	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	101	18	19	
Units: mm/hr				
arithmetic mean (standard deviation)				
Wk1,n=133,130,131,131,39,36,21,22,97,17,17,	-10.2 (± 17.11)	-7.7 (± 13.9)	-7.2 (± 16.3)	
Wk2,n=133,130,135,134,39,36,23,22,99,17,18	-10.2 (± 20.33)	-12.5 (± 16.71)	-13.6 (± 17.78)	
Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-12.3 (± 18.66)	-15.8 (± 17.49)	-11.3 (± 16.46)	
Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-18.3 (± 21.56)	-13.9 (± 23.29)	-17.6 (± 15.03)	
Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-19.9 (± 21.08)	-18.4 (± 23.07)	-17.9 (± 19.31)	
Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-21.1 (± 24.73)	-14.9 (± 17.78)	-8.8 (± 25.22)	
Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-7 (± 22.32)	-22 (± 23.6)	-20.5 (± 22.81)	
Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-21.1 (± 24.62)	-20.7 (± 20.65)	-11.4 (± 26.96)	
Wk28,n=119,110,na,na,34,35,21,21,89,17,19	-22.4 (± 22.9)	-26.1 (± 19.83)	-17.4 (± 24.77)	
Wk32,n=108,101,na,na,34,32,21,21,88,17,16	-25.5 (± 24.89)	-25.7 (± 21.14)	-23.1 (± 21.46)	
Wk36,n=107,98,na,na,32,31,21,20,87,18,16	-21.7 (± 25.4)	-26 (± 21.21)	-16.6 (± 23.31)	
Wk40,n=101,96,na,na,29,29,22,20,85,15,17	-22.2 (± 26.24)	-23.8 (± 22.96)	-22.9 (± 15.57)	

Wk44,n=98,93,na,na,28,28,20,19,85,15,16	-24.9 (± 25.66)	-22.3 (± 23.36)	-18.5 (± 21)	
Wk48,n=97,92,na,na,28,30,20,19,79,13,14	-23.9 (± 25.56)	-18.9 (± 26.41)	-20.2 (± 18.16)	
Wk52,n=94,91,na,na,29,28,20,18,83,16,16	-25.2 (± 27.88)	-27.4 (± 22.71)	-15.4 (± 22.53)	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.

Adverse event reporting additional description:

Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field "number of deaths resulting from adverse events" all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	18.0

Reporting groups

Reporting group title	Any AIN457 75 mg
-----------------------	------------------

Reporting group description:

Any AIN457 75mg included patients who originally were randomized to this treatment and placebo/abatacept-switchers to this dose.

Reporting group title	Any AIN457 150 mg
-----------------------	-------------------

Reporting group description:

Any AIN457 150mg included patients who originally were randomized to this treatment and placebo/abatacept-switchers to this dose.

Reporting group title	Any AIN457
-----------------------	------------

Reporting group description:

Any AIN457 included patients who originally were randomized to AIN457 75 mg or AIN457 150mg and placebo/abatacept-switchers to this dose.

Reporting group title	Abatacept
-----------------------	-----------

Reporting group description:

Abatacept

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo

Serious adverse events	Any AIN457 75 mg	Any AIN457 150 mg	Any AIN457
Total subjects affected by serious adverse events			
subjects affected / exposed	30 / 218 (13.76%)	28 / 215 (13.02%)	58 / 433 (13.39%)
number of deaths (all causes)	3	1	4
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			

subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibroadenoma of breast			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipoma			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer			
subjects affected / exposed	1 / 218 (0.46%)	1 / 215 (0.47%)	2 / 433 (0.46%)
occurrences causally related to treatment / all	1 / 1	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Venous thrombosis limb			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Cyst			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1

Device dislocation			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cystocele			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metrorrhagia			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectocele			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Dyspnoea			
subjects affected / exposed	1 / 218 (0.46%)	1 / 215 (0.47%)	2 / 433 (0.46%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			

subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Pulmonary hypertension			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Psychiatric disorders			
Delirium			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Laceration			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural headache			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	2 / 218 (0.92%)	0 / 215 (0.00%)	2 / 433 (0.46%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
Mitral valve incompetence			

subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral ischaemia			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Formication			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar radiculopathy			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningorrhagia			

subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perineurial cyst			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	2 / 218 (0.92%)	1 / 215 (0.47%)	3 / 433 (0.69%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertebrobasilar insufficiency			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Sudden hearing loss			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ischaemic			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal polyp			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic steatosis			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Liver disorder			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			
subjects affected / exposed	1 / 218 (0.46%)	1 / 215 (0.47%)	2 / 433 (0.46%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Acquired claw toe			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	1 / 218 (0.46%)	1 / 215 (0.47%)	2 / 433 (0.46%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			

subjects affected / exposed	2 / 218 (0.92%)	1 / 215 (0.47%)	3 / 433 (0.69%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis			
subjects affected / exposed	1 / 218 (0.46%)	1 / 215 (0.47%)	2 / 433 (0.46%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	0 / 218 (0.00%)	2 / 215 (0.93%)	2 / 433 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc disorder			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 218 (0.00%)	2 / 215 (0.93%)	2 / 433 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	4 / 218 (1.83%)	2 / 215 (0.93%)	6 / 433 (1.39%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoporotic fracture			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatoid arthritis			
subjects affected / exposed	0 / 218 (0.00%)	2 / 215 (0.93%)	2 / 433 (0.46%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			

subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye abscess			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	1 / 218 (0.46%)	1 / 215 (0.47%)	2 / 433 (0.46%)
occurrences causally related to treatment / all	1 / 1	1 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
H1N1 influenza			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster oticus			
subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint abscess			

subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis bacterial			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia influenzal			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 218 (0.00%)	0 / 215 (0.00%)	0 / 433 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	1 / 218 (0.46%)	0 / 215 (0.00%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			

subjects affected / exposed	0 / 218 (0.00%)	1 / 215 (0.47%)	1 / 433 (0.23%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Abatacept	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 137 (6.57%)	7 / 139 (5.04%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibroadenoma of breast			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoma			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary thyroid cancer			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Venous thrombosis limb			

subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Cyst			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device dislocation			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Cystocele			
subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metrorrhagia			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectocele			
subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Depression			
subjects affected / exposed	0 / 137 (0.00%)	1 / 139 (0.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laceration			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural headache			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 137 (0.00%)	1 / 139 (0.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Angina unstable			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			
subjects affected / exposed	0 / 137 (0.00%)	1 / 139 (0.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebral ischaemia			
subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Formication			

subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningorrhagia			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perineurial cyst			
subjects affected / exposed	0 / 137 (0.00%)	1 / 139 (0.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebrobasilar insufficiency			
subjects affected / exposed	0 / 137 (0.00%)	1 / 139 (0.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			

Sudden hearing loss			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Cataract			
subjects affected / exposed	0 / 137 (0.00%)	1 / 139 (0.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia			
subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal polyp			
subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct stone			

subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic steatosis			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver disorder			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue			

disorders			
Acquired claw toe			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis			
subjects affected / exposed	0 / 137 (0.00%)	1 / 139 (0.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc disorder			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporotic fracture			

subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye abscess			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis salmonella			
subjects affected / exposed	0 / 137 (0.00%)	1 / 139 (0.72%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1N1 influenza			

subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster oticus			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint abscess			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis bacterial			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia influenzal			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	1 / 137 (0.73%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			

subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth abscess			
subjects affected / exposed	0 / 137 (0.00%)	0 / 139 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Any AIN457 75 mg	Any AIN457 150 mg	Any AIN457
Total subjects affected by non-serious adverse events			
subjects affected / exposed	110 / 218 (50.46%)	114 / 215 (53.02%)	224 / 433 (51.73%)
Vascular disorders			
Hypertension			
subjects affected / exposed	20 / 218 (9.17%)	10 / 215 (4.65%)	30 / 433 (6.93%)
occurrences (all)	25	10	35
Nervous system disorders			
Headache			
subjects affected / exposed	18 / 218 (8.26%)	11 / 215 (5.12%)	29 / 433 (6.70%)
occurrences (all)	23	12	35
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	10 / 218 (4.59%)	10 / 215 (4.65%)	20 / 433 (4.62%)
occurrences (all)	12	10	22
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	16 / 218 (7.34%)	12 / 215 (5.58%)	28 / 433 (6.47%)
occurrences (all)	22	16	38
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	17 / 218 (7.80%)	15 / 215 (6.98%)	32 / 433 (7.39%)
occurrences (all)	26	20	46
Back pain			
subjects affected / exposed	12 / 218 (5.50%)	10 / 215 (4.65%)	22 / 433 (5.08%)
occurrences (all)	16	11	27
Rheumatoid arthritis			
subjects affected / exposed	19 / 218 (8.72%)	22 / 215 (10.23%)	41 / 433 (9.47%)
occurrences (all)	24	27	51
Infections and infestations			
Bronchitis			
subjects affected / exposed	10 / 218 (4.59%)	12 / 215 (5.58%)	22 / 433 (5.08%)
occurrences (all)	11	17	28
Influenza			
subjects affected / exposed	7 / 218 (3.21%)	13 / 215 (6.05%)	20 / 433 (4.62%)
occurrences (all)	7	17	24
Nasopharyngitis			
subjects affected / exposed	24 / 218 (11.01%)	17 / 215 (7.91%)	41 / 433 (9.47%)
occurrences (all)	42	33	75
Rhinitis			
subjects affected / exposed	8 / 218 (3.67%)	12 / 215 (5.58%)	20 / 433 (4.62%)
occurrences (all)	10	15	25
Upper respiratory tract infection			
subjects affected / exposed	18 / 218 (8.26%)	21 / 215 (9.77%)	39 / 433 (9.01%)
occurrences (all)	28	34	62
Urinary tract infection			
subjects affected / exposed	16 / 218 (7.34%)	10 / 215 (4.65%)	26 / 433 (6.00%)
occurrences (all)	19	10	29
Metabolism and nutrition disorders			
Hypercholesterolaemia			
subjects affected / exposed	7 / 218 (3.21%)	7 / 215 (3.26%)	14 / 433 (3.23%)
occurrences (all)	7	7	14
Hyperlipidaemia			
subjects affected / exposed	6 / 218 (2.75%)	11 / 215 (5.12%)	17 / 433 (3.93%)
occurrences (all)	6	11	17

Non-serious adverse events	Abatacept	Placebo	
-----------------------------------	-----------	---------	--

Total subjects affected by non-serious adverse events subjects affected / exposed	58 / 137 (42.34%)	36 / 139 (25.90%)	
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	5 / 137 (3.65%) 5	4 / 139 (2.88%) 4	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	9 / 137 (6.57%) 10	4 / 139 (2.88%) 4	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	6 / 137 (4.38%) 6	8 / 139 (5.76%) 9	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	9 / 137 (6.57%) 9	0 / 139 (0.00%) 0	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) Back pain subjects affected / exposed occurrences (all) Rheumatoid arthritis subjects affected / exposed occurrences (all)	5 / 137 (3.65%) 7 6 / 137 (4.38%) 6 6 / 137 (4.38%) 6	1 / 139 (0.72%) 1 2 / 139 (1.44%) 2 6 / 139 (4.32%) 8	
Infections and infestations Bronchitis subjects affected / exposed occurrences (all) Influenza subjects affected / exposed occurrences (all) Nasopharyngitis	5 / 137 (3.65%) 7 1 / 137 (0.73%) 1	0 / 139 (0.00%) 0 1 / 139 (0.72%) 1	

subjects affected / exposed occurrences (all)	8 / 137 (5.84%) 11	4 / 139 (2.88%) 7	
Rhinitis subjects affected / exposed occurrences (all)	3 / 137 (2.19%) 3	1 / 139 (0.72%) 1	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	6 / 137 (4.38%) 7	9 / 139 (6.47%) 9	
Urinary tract infection subjects affected / exposed occurrences (all)	8 / 137 (5.84%) 8	2 / 139 (1.44%) 3	
Metabolism and nutrition disorders			
Hypercholesterolaemia subjects affected / exposed occurrences (all)	10 / 137 (7.30%) 10	6 / 139 (4.32%) 6	
Hyperlipidaemia subjects affected / exposed occurrences (all)	1 / 137 (0.73%) 1	2 / 139 (1.44%) 2	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
04 August 2011	Amendment 1 introduced the following changes: Wording on the patient number for re-screened patient was removed. Each patient was tracked using a unique patient identifier, that was applied within the database but not visible for the investigator and therefore the sentence was misleading. A serum biomarker sample log was added. Typographic errors were corrected and some sentences clarified. The changes described in this amended protocol were non-substantial and did not require IRB/IEC approval prior to implementation.
08 January 2014	Amendment 2 introduced the following change(s): Amending the handling of missing values in the analysis plan in line with guidance received in discussions with FDA. The sequence of the hierarchical testing strategy was aligned with Draft FDA guidance released May 2013 for clinical trials in patients with rheumatoid arthritis. This placed more emphasis on DAS28 and parameters related to physical function, in particular HAQ-DI, and accounted for other data obtained from Phase IIb studies in the RA development program with secukinumab and newly available data from other RA programs. Implementing a full primary analysis after all patients completed 24 weeks replacing a potential futility analysis after 25-50% of patients had completed Week 16. Simplifying the protocol section on study drug preparations and administration, including removing details covered in pharmacist manual. This resulted in improved patient convenience for the remainder of the trial, as patient did not have to stay at site for a mandatory length of time after administration of study drug was completed. Providing investigator with more flexibility to be able to apply own best clinical judgment when study treatment interruptions for safety reasons were indicated, and clarification of the requirements to be observed with regards to live vaccines. Clarification on the restrictions with regards to concomitant medications, mostly to clarify what had to be followed (otherwise considered protocol deviation) as compared to what is only a general guidance (indicated by words like 'should'). Clarification that any laboratory abnormalities that in the judgment of the investigator were clinically significant and were deemed to place the patient at a safety risk for continuation in the study should result in study treatment discontinuation, and updated general guidance for investigators with regards to notable laboratory abnormalities for the most relevant lab parameters.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use <https://www.novctrd.com/CtrdWeb/home.novfor> for complete trial results.

Notes: